A clinical trial evaluating octreotide long-acting injection reached completed status as of September 11, 2026. The study, registered as NCT07814651, is titled "A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly." It is listed as a Phase 2 trial focused on patients with acromegaly.
The trial examined safety, efficacy, pharmacokinetics, and pharmacodynamics of the octreotide long-acting formulation in this patient population. Its listing on ClinicalTrials.gov now shows a status of completed, indicating the study has concluded its planned activities as of the recorded date.
No results have been reported alongside this status update, and this brief does not characterize outcomes, benefits, or safety findings from the trial. Octreotide is an approved compound, and this update pertains specifically to a registered study of its long-acting injection formulation in acromegaly.
Readers interested in background on this compound can consult the compound overview for additional context.